Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

tiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... international research team including DESY scientists has observed tiny ... team reports in the journal Science that ... inside the nanodroplets. It is the first time that ... larger samples of what is known as superfluid helium, ... our best expectations," says Andrey Vilesov of the University ...
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
(Date:8/21/2014)... 21, 2014  Four-dimensional (4-D) printing develops materials ... external stimuli such as changes in temperature. This ... effect in multiple industries.  In the near future, ... printing objects ranging from human organs to parts ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... DUBLIN, Calif., Feb. 28 Microchip Biotechnologies, ... develop a front-end,microfluidic based sample preparation system ... The goal of the project is to ... MBI,s,Microscale-On-chip-Valves (MOV(TM)) for Superscalar Pyrosequencing. "Using,MBI,s MOV ...
... US Oncology Holdings, Inc. ("Holdings",or the "Company"), the ... the nation,s largest cancer services companies, reported revenue of,$771.6 ... million,net loss of $14.8 million and operating cash flow ... For the year ended December 31, 2007, the,Company reported ...
... N.J., Feb. 28 Pharmacopeia,(Nasdaq: PCOP ), ... novel,small molecule therapeutics, today announced advancements for two ... President, Clinical and,Regulatory Affairs, has been promoted to ... role of S. David Kimball, Ph.D., Senior,Vice President, ...
Cached Biology Technology:Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 4US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 5US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 6US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 7US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 8US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 9US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 10US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 11US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 12US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 13US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 14US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 15US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 16US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 17US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 18US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 19US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 20US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 21US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 22US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 23US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 24US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 25US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 26Pharmacopeia Announces Management Team Changes 2Pharmacopeia Announces Management Team Changes 3Pharmacopeia Announces Management Team Changes 4Pharmacopeia Announces Management Team Changes 5
(Date:8/20/2014)... HOUSTON, Aug. 20, 2014 George E. Fox, a John ... University of Houston (UH), was named a fellow in the ... (ISSOL). , Fox is one of four members ... Spain chosen as fellows in 2014. Fellows are elected ... With more than 500 members from more than 20 countries, ...
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
(Date:8/20/2014)... Bay Area Lyme Foundation, which aims to make Lyme ... new research published in an upcoming issue of the ... . The findings show that ticks that carry ... year, making the threat of Lyme disease year-round. The ... Public Health (CDPH) Vector-borne Disease Section and University of ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... N.Y. With fewer than a dozen flowering plants out ... intake, people need to tap unused plants to feed the ... Susan McCouch in the Comment feature of the July 4 ... population growth and rising incomes around the world, researchers estimate ...
... TORONTO - A team of Toronto-based researchers may be one ... cells for use in research and therapy. Induced pluripotent ... research because they can flexibly develop into many different types ... proteins that control their generation are largely unknown. But ...
... Gondwana Research , has revealed the past position ... how they formed the supercontinent Gondwana 165 million years ... National University and Geoscience Australia, have helped clear up ... they should be positioned when drawing up a picture ...
Cached Biology News:To feed the future, we must mine the wealth of the world's seed banks today 2Toronto team ID proteins key in stem cell production 2
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Biology Products: